Dr. Alex Ricart discusses the exciting advancements in antibody-drug conjugates (ADCs) for treating cancers like leukemia, lymphoma, and solid tumors. Here, Dr. Ricart highlights how the approved ADCs have already shown remarkable results enhancing traditional chemotherapy, particularly in relapsed refractory disease. He also shares innovative study designs and future breakthroughs in ADC technology, including new antibody fragments and hydrophilic linkers, and underscores the importance of better patient selection to maximize efficacy and minimize toxicity.